Pathological Response After Neoadjuvant Treatment on NSCLC
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFundación GECP
About this trial
This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.
Eligibility criteria
Qualifiers
Patients with resectable stage IIIA disease (according to American Joint Committee on Cancer [AJCC] lung cancer edition 7 or 8) who were included in the Tumor Thoracic Registry data base and in stage IIIA clinical trials which the sponsor is Fundación GECP.
Patients with histologically N2 involvement confirmed
Patients diagnosed as stage IIIA from 2010 and 2017
Patients who have received neoadjuvant platinum-based treatment and surgery
Disqualifiers
Patients who received chemoradiotherapy neoadjuvant treatment
Patients who were not resected after neoadjuvant treatment
Patients who were diagnosed after June 2017
Trial design
Treatments tested in this trial
- Cisplatin
- Carboplatin
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov